Biotech startup Undecimal Bio raises £14m seed round led by 4BIO Capital and IQ Capital
This article covers Undecimal Bio, a biotech startup, which has raised an oversubscribed £14m seed funding round to develop DELiveri, its AI-enabled platform for directing siRNA therapeutics to cell types beyond the liver. The funding will support further platform development, early renovascular programmes and expansion of its Cambridge laboratories, aiming to broaden the range of diseases addressable with RNA interference therapies.
Undecimal Bio, a biotech startup spun out of Eleven Therapeutics, has raised an oversubscribed £14 million seed funding round to develop DELiveri, its AI-enabled platform for directing siRNA therapeutics to cell types beyond the liver. The money will bankroll further platform development, early renovascular programmes and expansion of its Cambridge laboratories — progress that could help unlock broader applications for RNA interference medicines.
Why it matters
RNA interference therapies have delivered clear clinical benefits where delivery to the liver is straightforward, but getting siRNA into other tissues has remained a major technical barrier. Undecimal Bio’s seed round signals continued interest from biotech investors in platform technologies that aim to solve delivery, a problem that would expand the range of diseases addressable with genetic medicines.
The company is targeting renovascular diseases first, an area with few disease-modifying treatments. If DELiveri can reliably move siRNA into the relevant cell types, it would shift these programmes from symptomatic care towards potentially durable, target-specific silencing of disease pathways.
Inside the product
DELiveri couples large-scale chemical screening with machine learning to find conjugates that carry siRNA into particular cells. The platform screens combinatorial libraries of candidate ligands and converts cells into what the company describes as molecular radars that detect productive delivery at single-molecule resolution. High-throughput datasets are then analysed by agentic AI to decode structure-activity relationships and score candidate conjugates.
Undecimal Bio says initial work focuses on renovascular programmes, with the funding allocated to advance these assets and grow its Cambridge team. The company runs laboratories at the Cancer Research UK Cambridge Institute and maintains operations in Tel Aviv as well as Cambridge, United Kingdom. It has also entered several research collaborations with large pharmaceutical companies, terms of which remain undisclosed.
Who are the investors?
The £14 million seed round was co-led by 4BIO Capital and IQ Capital and described as oversubscribed. Other participants include Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital.
The company has already reflected investor influence in its governance. The Board of Directors includes representatives from 4BIO Capital, IQ Capital and Harel Technologies alongside co-founders Yaniv Erlich and Shaul Ilan. Verve Ventures joins as a board observer.
Investors cited in the filing are backing a platform approach and the potential to partner with larger pharma groups; the company has confirmed undisclosed research collaborations with major pharmaceutical firms as part of its development strategy.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Yaniv Erlich, Co-founder & CEO at Undecimal Bio, said:
The hard problem in RNAi was never the silencing, it was getting the molecule to the right cell, Our in-vivo validated DELiveri platform can screen large chemical spaces at an unprecedented pace, generating massive data for our legions of AI agents to decipher the structure-activity relationship and score the best candidates. We are excited to bring these advances to develop the next generation of siRNA therapeutics for the benefit of patients.
The bigger picture
Undecimal Bio’s funding and dual-site footprint underline the cross-border nature of modern UK biotech: early-stage science in Cambridge paired with operational ties to Tel Aviv. The deal sits within a broader trend of investors backing convergence between wet lab screening and AI-driven analysis to overcome long-standing delivery challenges in genetic medicines.
If DELiveri proves reproducible in vivo and scalable, it could attract further partnership investment from large pharma and accelerate clinical translation across indications that today remain out of reach for siRNA therapies. The outcome will be watched closely by biotech investors and the wider UK life sciences ecosystem as a test case for platform-first startups aiming to broaden the reach of RNAi.
They've invested in Undecimal Bio
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 4BIO Capital( ) We are a London-based venture capital firm specialising in life sciences, with a... London  | ||||
 IQ Capital( ) IQ Capital is a dedicated European deep tech venture capital firm, specialising ... London, Cambridge | ||||
 Verve Ventures( ) | ||||
 Entree Capital( ) Entrée Capital is a venture capital firm focusing on early-stage investments, su... London | ||||
 Kerna Ventures( ) | ||||
 Saras Capital( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK